Captor Therapeutics (CTX) investor relations material

Executive summary

• Advanced clinical and preclinical pipeline with multiple oncology and immunology assets, including viadrudomide and vratitoclax, progressing through key milestones.

• Focused on targeted protein degradation (TPD) for oncology and autoimmune diseases, with five proprietary drug development projects and several advanced candidates.

• Continued R&D investments led to a net loss, typical for the biotech sector at this stage, as projects are not yet commercialized.

• No significant changes in group structure or business model; main activities remain R&D and partnership/licensing.

Financial highlights

• Revenue from R&D services was 328k PLN in Q1 2026, down from 2,606k PLN in Q1 2025.

• Net loss for Q1 2026 was -11,375k PLN, compared to -10,719k PLN in Q1 2025.

• Operating loss was 11,262k PLN in Q1 2026.

• Cash and financial instruments totaled 17.9m PLN as of March 31, 2026, excluding proceeds from a share issue.

• Total assets were 26,097k PLN as of March 31, 2026; equity was 12,054k PLN.

Outlook and guidance

• Ongoing clinical study for viadrudomide in hepatocellular carcinoma.

• Vratitoclax preparations for clinical trials continue, with technical batch produced and clinical batch planned for Q3.

• R&D spending expected to increase, especially for projects beyond viadrudomide and vratitoclax.

• Current cash position, including post-period capital raise, expected to fund operations through Q3 2027.

• Key future drivers: partnership negotiations, research progress, and grant funding.